top of page

NCI-2019-04523

Updated: Feb 21

A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions


It's a Phase 1/2 study looking at a drug called IDE196 in patients with certain types of solid tumors. These tumors have mutations in GNAQ/11 or PRKC genes.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) This is a research study exploring how combining radiation therapy with dual immune check

 
 
 
NCI-2024-05588

A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) The INSI

 
 
 
NCI-2022-08569

Randomized Phase III Trial of mFOLFIRINOX /- Nivolumab vs. FOLFOX /- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma This randomized Phase III research

 
 
 

Comments

bottom of page